Prediction of Preeclampsia & Other Obstetric Complications by Serum Homocysteine & Doppler

Second Trimester Maternal Serum Homocysteine Level & Uterine Artery Doppler for Prediction of Preeclampsia , Intra-Uterine Growth Retardation (IUGR) & Other Obstetric Complications

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT02541110

Enrollment

200

Registered

2015-09-04

Start date

2015-09-30

Completion date

2016-02-29

Last updated

2015-09-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

IUGR, Preeclampsia

Brief summary

Second trimester homocysteine & uterine artery doppler will be assessed& the cases will be followed up till delivery for development of preeclampsia, IUGR(intra-uterine growth retardation) & other obstetric complications.

Detailed description

Spontaneous pregnancies with no risk factors will be included. Fasting plasma total homocysteine level samples will be collected between 15th & 19th weeks. Uterine artery doppler between 18th & 22nd weeks. Method 1: Screen positive cases will be considered if homocysteine level above 6.3umol/l Method 2: Screen positive cases will be considered if they had bilateral notches and a mean resistivity index (RI) above 0.55, or unilateral notches and a mean RI above 0.65, or absence of notches and a mean RI above 0.7. Method 3: Screen positive cases will be considered if they had bilateral notches and a mean RI above 0.55, or unilateral notches and a mean RI above 0.65, or absence of notches and a mean RI above 0.7 combined with homocysteine cut off value of 6.3umol / l.

Interventions

None listed

Study design

Observational model

CASE_CONTROL

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

FEMALE

Age

18 Years to 40 Years

Healthy volunteers

Yes

Inclusion criteria

* spontaneous pregnancies with no risk factors

Exclusion criteria

* multiple pregnancies * non intact renal function * hypertension * diabetes * folic acid supplements * antifolate drugs

Design outcomes

Primary

Measure	Time frame
Number of pregnants who developed preeclampsia, those who developed IUGR alone and those who developed other obstetric complications as preterm labour and placental abruption	4 months

Contacts

Primary Contactsuzy abdelaziz, M.D.

suzyabdelaziz92@gmail.com01003726195

Outcome results